Previous Meetings

GBCC 2016

Global Breast Cancer Conference 2016

11:10-12:10
Plenary Lecture 1
Venue: Halla Hall
  • Current Indications of Radiation Therapy
    Bruce Haffty (Rutgers Cancer Institute of New Jersey, U.S.A.)
12:10-13:10
Luncheon Symposium 1
Venue: Halla Hall
  • Optimized Endocrine Treatment Strategy in ER+ Post Meno ABC Management
    Antonio Llombart Cussac (Medical Oncology Hospital Arnau de Vilanova in Valencia, Spain)
13:30-14:30
Plenary Lecture 2
Venue: Halla Hall
  • Precision Medicine Based on Genomics in Breast Cancer
    Jorge Reis-Filho (Memorial Sloan Kettering Cancer Center, U.S.A.)
14:40-15:50
Symposium 1
DCIS – What’s New?
Venue: Halla Hall
  • Molecular and Pathological Changes during Progression from in situ to Invasive Cancer
    So Yeon Park (Seoul National Univ. College of Medicine, Seoul National Univ. Bundang Hospital, Korea)
  • Personalized Treatment of DCIS
    Jeong Eon Lee (Samsung Medical Center, Korea)
  • No Surgery for DCIS?
    Mehra Golshan (Dana Farber Cancer Institute, Brigham and Women’s Hospital, U.S.A.)
Panel Discussion 1
Circulating Tumor DNA - Myth or Reality?
Venue: Lotus Hall
  • Clinical Utility of CtDNA in Breast Cancer
    Jorge Reis-Filho (Memorial Sloan Kettering Cancer Center, U.S.A.)
  • Clinical Implications of Circulating Tumor Cells of Breast Cancer Patients: Role of Epithelial-mesenchymal Plasticity
    Seung Il Kim (Yonsei Univ. College of Medicine, Korea)
Oral Presentation 1
Venue: Weolla Room
  • DETERMINATION OF ANTI-CANCER MECHANISMS OF GOSSYPETIN AND LUTEOLIN IN COMBINATION WITH CHEMOTHERAPEUTIC CYCLOPHOSPHOAMIDE ON MCF-7 HUMAN BREAST CANCER CELL LINES
    Elif Candan (Fatih Univ., Turkey)
  • DEVELOPMENT AND VALIDATION OF PERSONALIZED EX VIVO PLATFORM MIMICKING PATIENT HETEROGENEOUS TUMOR MICROENVIRONMENT TO ENABLE PERSONALIZED TREATMENT FOR BREAST CANCER
    Govind Babu K (Kidwai, India)
  • HI-PLEX FOR HIGH THROUGHPUT MUTATION SCREENING OF BRCA1, BRCA2, TP53, AND PALB2 IN BREAST AND OVARIAN CANCER PATIENTS
    Wei Xiong Wen (Cancer Research Malaysia, Malaysia)
  • DEAD-BOX RNA HELICASE DP103 AS A BIOMARKER FOR THERAPEUTIC RESPONSE TO DOCETAXEL
    Alan Prem Kumar (National Univ. of Singapore, Singapore)
  • THE BASIC FACTS OF KOREAN BREAST CANCER IN 2013: RESULTS OF A NATIONWIDE SURVEY AND BREAST CANCER REGISTRY DATABASE
    Sun Young Min (Kyung Hee Univ. School of Medicine, Korea)
  • IDENTIFICATION OF MOLECULES ASSOCIATED WITH TAMOXIFEN RESISTANCE THROUGH GENE EXPRESSION PROFILING OF TAMOXIFEN-RESISTANT BREAST CANCER CELLS
    Sang Hyeok Woo (Korea Institute of Radiological & Medical Sciences, Korea)
  • INHERITED PREDISPOSITION FOR BREAST CANCER IN DIVERSE HEREDITARY CANCER SYNDROMES: STRATEGIES FOR SYNDROME SPECIFIC GENETIC TESTING AND RISK MANAGEMENT
    Rajiv Sarin (Tata Memorial Centre, India)
  • EFFICACY AND SAFETY OF EVEROLIMUS AND EXEMESTANE IN PATIENTS WITH ADVANCED BREAST CANCER FROM ASIA AND AFRICA: ASIAN SUBSET RESULTS FROM THE PHASE 3B EVEREXES STUDY
    Young-Hyuck Im (Samsung Medical Center, Korea)
16:00-17:10
Symposium 2
Optimal Breast Irradiation for Breast Cancer
Venue: Halla Hall
  • Current Perspectives on Radiation Therapy in Autologous and Prosthetic Breast Reconstruction
    Won Park (Samsung Medical Center, Korea)
  • Regional Nodal Management in Breast Cancer: From Z11 to AMAROS
    Bruce Haffty (Rutgers Cancer Institute of New Jersey, U.S.A.)
  • Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence
    Sung-Ja Ahn (Chonnam National Univ. Medical School, Korea)
Panel Discussion 2
Biomarker Driven Clinical Trial Design in the Era of Precision Medicine in Breast Cancer
Venue: Lotus Hall
  • A Molecular Portrait of Asian Breast Cancer: Multi-omics and Immune Profiling of a Prospective Breast Cancer Cohort Enriched in Young, Premenopausal Patients
    Zhengyan Kan (Pfizer, Inc., U.S.A.)
  • Innovative Clinical Trial in the Era of Genomics
    Yeon Hee Park (Samsung Medical Center, Korea)
Education Session 1
Current and Future Role of Neoadjuvant Therapy for Breast Cancer
Venue: Weolla Room
  • Surgical Issues in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
    Mehra Golshan (Dana Farber Cancer Institute, Brigham and Women’s Hospital, U.S.A.)
  • Neoadjuvant Therapy of Early Stage HER 2-positive Breast Cancer: Latest Evidence and Clinical Implications
    In Hae Park (National Cancer Center, Korea)
  • Neoadjuvant Endocrine Therapy in Breast Cancer
    Wonshik Han (Seoul National Univ. Hospital, Korea)
Back to Previous Meetings